LNP formulations were prepared as previously described (48 (link)). Briefly, lipids dissolved in ethanol at a molar ratio of 50:10:38.5:1.5 of ionizable:helper:structural:polyethylene glycol were mixed with acidified mRNA at a ratio of 3:1 mRNA:lipid. Formulations were dialyzed against PBS (pH 7.4) for at least 18 hours, concentrated using Amicon Ultra centrifugal filters (EMD Millipore Corp., Merck KGaA, Darmstadt, Germany), passed through a 0.22-μm filter, and stored at 4°C until use. Particle size was measured by dynamic light scattering and found to be <100 nm; encapsulation was >90%, as measured by the Quant-iT RiboGreen RNA quantitation kit (Thermo Fisher Scientific), and endotoxin was <10 endotoxin units (EU)/ml. mRNA was formulated with DOTAP (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s recommended protocol.
In Vitro mRNA Synthesis and LNP Formulation
LNP formulations were prepared as previously described (48 (link)). Briefly, lipids dissolved in ethanol at a molar ratio of 50:10:38.5:1.5 of ionizable:helper:structural:polyethylene glycol were mixed with acidified mRNA at a ratio of 3:1 mRNA:lipid. Formulations were dialyzed against PBS (pH 7.4) for at least 18 hours, concentrated using Amicon Ultra centrifugal filters (EMD Millipore Corp., Merck KGaA, Darmstadt, Germany), passed through a 0.22-μm filter, and stored at 4°C until use. Particle size was measured by dynamic light scattering and found to be <100 nm; encapsulation was >90%, as measured by the Quant-iT RiboGreen RNA quantitation kit (Thermo Fisher Scientific), and endotoxin was <10 endotoxin units (EU)/ml. mRNA was formulated with DOTAP (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s recommended protocol.
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization : Moderna Therapeutics (United States)
Protocol cited in 28 other protocols
Variable analysis
- Whether the NTPs were included at equimolar concentrations (process A) or custom molar ratios (process B)
- MRNA purity and quality after purification by 2'-deoxy-T20 oligo affinity chromatography (process A) or ion pair RP-HPLC (process B)
- Particle size of the LNP formulations
- Encapsulation efficiency of the mRNA in the LNP formulations
- Endotoxin levels in the LNP formulations
- The mRNA synthesis process using T7 RNA polymerase-mediated transcription from a linearized DNA template
- The LNP formulation process, including the molar ratio of lipid components and the mRNA:lipid ratio
- The buffer and storage conditions for the purified mRNA and LNP formulations
- None explicitly mentioned
- None explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!